Close Menu

NEW YORK (GenomeWeb) – Newly public Co-Diagnostics reported today revenues of $7,662 in 2017 versus no revenues in the prior year.

For the 12-month period ended Dec. 31, Co-Diagnostics' net loss swelled to $7 million, or $.63 per share, from $1.9 million, or $.20 per share, in 2016.

R&D costs climbed to $1 million from $731,474, while SG&A expenses rose to $3.5 million from $919,001.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.